Olympus reviewed the following literature titled "prophylactic antibiotics may be unnecessary in gastric endoscopic submucosal dissection due to the low incidence of bacteremia." background and aims: endoscopic submucosal dissection (esd) was developed as a feasible and reliable treatment for gastrointestinal mucosal or submucosal lesions.Bacteremia may occur after esd.Currently, the use of prophylactic antibiotics after gastric esd is controversial.This study was designed to explore the value of prophylactic antibiotics in the treatment of gastric mucosal and submucosal lesions after esd.Methods: in this prospective study, in total, 103 patients who underwent gastric esd were included, and the frequency of bacteremia and changes in inflammation-related indicators before and after the procedure were investigated.The patients did not receive prophylactic antibiotics.Results: the body temperature (t), white blood cell count (wbc), and procalcitonin (pct) and c-reactive protein (crp) levels did not significantly differ between the perforation group (n=40) and nonperforation group before gastric esd (n=63) (all p>0.05).The t, wbc, and crp levels (all p<0.05) in the patients with perforation were significantly higher than those in the patients without perforation 24 h after gastric esd.The incidence of bacteremia did not significantly differ between the two groups (all p>0.05).In total, 6 of 309 blood cultures were cultured with bacteria.The total frequency of bacteremia in the perforation and nonperforation groups was 2.5% and 3.2%, respectively.No sepsis occurred in any patients.Conclusion: regardless of whether perforation occurred after gastric esd, the incidence of bacteremia was transient and low.Therefore, based on our single-center study in china, prophylactic antibiotics may not be necessary in patients with intraoperative perforation during gastric esd.Type of adverse events/number of patients: perforations - 40 patients.Blood cultures cultured bacteria - 6 cultures.Fever - 15 patients.This literature article requires 14 reports.The related patient identifiers are as follows: for 6 patients with bacterial growth and other adverse events.(b)(6): kd-620lr (patient no.1), (b)(6): fd-412lr (patient no.1), (b)(6): kd-620lr (patient no.2), (b)(6): fd-412lr (patient no.2), (b)(6): kd-620lr (patient no.3), (b)(6): fd-412lr (patient no.3), (b)(6): kd-620lr (patient no.4), (b)(6): fd-412lr (patient no.4), (b)(6): kd-620lr (patient no.5), (b)(6): fd-412lr (patient no.5), (b)(6): kd-620lr (patient no.6), (b)(6): fd-412lr (patient no.6), (b)(6): kd-620lr (other adverse event), (b)(6): fd-412lr (other adverse event).This medwatch report is for patient identifier: (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.This supplemental report includes a correction to e4.Information added that was inadvertently not included on the initial medwatch.Olympus will continue to monitor field performance for this device.
|